Note that the structure and content of HemOnc.org are constantly undergoing evolution, such that information that you read here might be outdated. This page was last reviewed and updated in October 2019.

Introduction

Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combine measures of efficacy, toxicity, quality of life, and financial toxicity into a metric of value that can be used to influence treatment decisions. Our coverage of value frameworks will expand over time.

ASCO Value Framework

ESCAT

2018: A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

ESMO Magnitude of Clinical Benefit Scale

2015 (Version 1.0): A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) PubMed
2017 (Version 1.1): ESMO-Magnitude of Clinical Benefit Scale version 1.1

NCCN Evidence Blocks

2016: NCCN Evidence Blocks PubMed

Comparisons

ASCO Value Framework vs. ESMO-MCBS

2017: Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? PubMed

ASCO Value Framework vs. NCCN Evidence Blocks

2017: Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology PubMed

Frequently asked questions

Q: Do you plan to add value measures to HemOnc.org?
A: At some point in the future, we may add value measures to some regimens; however, given that these frameworks are recently introduced and undergoing frequent revision, we will continue to monitor their development, for now.

Value frameworks

Contents